The company offers a portfolio of specialty therapeutics including Flutiform (asthma), Pentasa (ulcerative colitis/Crohn's disease), and Nasonex (allergic rhinitis), alongside diagnostics and contract manufacturing services. KYORIN has development and commercialization agreements with innovators like Hyfe Inc. for digital therapeutics focused on chronic cough.
Cyborg Score Rationale
KYORIN operates as an established Japanese pharmaceutical player with a diverse product portfolio and dividend history. However, earnings per share has fallen approximately 8.9% per year over the past five years, and the company is not generating free cash flows despite being able to cover dividends, raising sustainability concerns.
Top Insights
Market capitalization is approximately ¥88.53 billion
The company maintains a ¥32.00 dividend yield of 3.8%
Secured exclusive rights to develop and commercialize aclidinium bromide in Japan for COPD treatment
Company employs approximately 2,000 people as of September 2025
Named Competitors
Ethical/Generic Pharmaceuticals — Larger diversified Japanese pharma with global reach
Specialty Pharmaceuticals — Japanese pharmaceutical focusing on oncology and cardiology
Contract Manufacturing/Generics — Global generic and biosimilar competitor
Recent Developments
(February 2025) Affirmed dividend of ¥32.00 per share with 3.8% dividend yield
(June 2024) Entered licensing agreement with Almirall for COPD drug aclidinium bromide exclusive rights in Japan
Open the full interactive KYORIN Pharmaceutical Co., Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.